Benchling

Benchling is a cloud-based platform powering biotechnology R&D. Its platform, the Benchling R&D Cloud, aims to replace traditional tools with a comprehensive digital environment tailored for life sciences workflows. Its features include experiment design and tracking, a cloud-based electronic lab notebook, molecular biology software for tasks like DNA sequence analysis, inventory management, data visualization tools, and collaboration capabilities. 

The company surpassed USD 200 million in annualized revenue in 2024, with a 90% YoY increase in subscription revenue reported in 2022. Benchling initially filed confidential paperwork for an IPO in late 2021 but has not yet gone public as of early 2024.

Key customers and partnerships

Benchling serves a diverse customer base across the biotechnology industry. As of 2024, over 200,000 scientists at more than 1,200 organizations globally use Benchling as their central system for R&D data management and analysis, including several global biopharma companies such as Regeneron, Gilead Sciences, and Sanofi. The company also works with numerous biotech startups and emerging companies in areas like gene editing, synthetic biology, and cell therapy. As of September 2024, notable customers included Beam Therapeutics,  Editas Medicine, Verve Therapeutics, and Mammoth Biosciences.

In March 2023, Benchling launched a partner program to expand its ecosystem, bringing in consulting and implementation partners like 20/15 Visioneers, Astrix, and BASE Life Science to provide customers with more options for deploying and integrating Benchling into their R&D environments. Additionally, in June 2024, Benchling announced a significant partnership with Sanofi to transition the latter’s R&D systems to Benchling's cloud platform, supporting Sanofi's AI-powered R&D initiatives.